Pieris Pharmaceuticals, Inc. (PIRS)
| Market Cap | 114.58M |
| Revenue (ttm) | 29.32M |
| Net Income (ttm) | -37.23M |
| Shares Out | 54.48M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $1.81 |
| Previous Close | $1.93 |
| Change ($) | -0.12 |
| Change (%) | -6.22% |
| Day's Open | 1.90 |
| Day's Range | 1.80 - 1.93 |
| Day's Volume | 535,258 |
| 52-Week Range | 1.70 - 3.64 |
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...
Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the program,...
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in he...
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -8.33% and -50.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 5.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% over the past year to ($0.26)...
Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZen...
On Tuesday, March 30, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target coll...
BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno...
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -62.50% and -67.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2020 Results - Earnings Call Transcript
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.
NEW YORK, July 21, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).
Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q1 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q3 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The stock of Pieris Pharmaceuticals has made a nice move so far in September.
Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q2 2019 Results - Earnings Call Transcript
Here are four stocks that appear to be at or near a breakout point: Enphase Energy, Inc.
Investors need to pay close attention to Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.
Shares have fallen by 30% since my initial and update articles.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q1 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About PIRS
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment o... [Read more...]
| Industry Biotechnology | |
| CEO Stephen Yoder | Employees 111 |
| Stock Exchange NASDAQ | Ticker Symbol PIRS |
Financial Performance
In 2020, PIRS's revenue was $29.32 million, a decrease of -36.64% compared to the previous year's $46.28 million. Losses were -$37.23 million, 46.2% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for PIRS stock is "Strong Buy." The 12-month stock price forecast is 9.00, which is an increase of 397.24% from the latest price.